ipalolimab

Ipalolimab (JS003) is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Developed by Junshi Biosciences, it acts as an immune checkpoint inhibitor by blocking the interaction between PD-1 on T cells and its ligands, PD-L1 and PD-L2, which are often overexpressed on tumor cells. This blockade prevents the inhibitory signaling that typically suppresses T-cell activity, thereby restoring and enhancing the anti-tumor immune response. Ipalolimab is currently being evaluated in clinical trials, frequently in combination with other immunotherapies such as tovorelimab (an anti-TIGIT antibody) or targeted agents like regorafenib, for the treatment of advanced solid tumors, including gastric and gastroesophageal junction adenocarcinomas.

Other names

ipalolimabum